unstable angina (anginal symptoms at rest) or new onset angina (i.e., began within the last  months).
Unstable angina, new-onset angina within last  months, myocardial infarction within the last  months prior to Day  of Cycle , or current congestive heart failure classified as New York Heart Association Class II or higher
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Patients with unstable angina, new onset angina within the last  months, myocardial infarction within the last  months, and current congestive heart failure New York Heart Association class III or higher
Patients with cardiac disease defined as one of the following are not eligible:\r\n* Congestive heart failure > class II New York Heart Association (NYHA)\r\n* Unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months)\r\n* Myocardial infarction within the past  months
Active or clinically significant cardiac disease including any of the following:\r\n* Unstable angina (eg, anginal symptoms at rest) or onset of angina within  months prior to initiating study treatment\r\n* Myocardial infarction within  months prior to initiating study treatment\r\n* New York Heart Association (NYHA) class III or IV congestive heart failure
Unstable angina (angina symptoms at rest), new-onset angina (begun within the last  months)
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Unstable angina (symptoms of angina at rest) or new-onset angina (within last  months before randomization)
History or current evidence of uncontrolled cardiovascular disease including, but not limited to, the following conditions:\r\n* Congestive heart failure of New York Heart Association (NYHA) class III or IV\r\n* Unstable angina (symptoms of angina at rest) or new-onset angina =<  months before the start of anetumab ravtansine
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (angina symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Unstable angina (anginal symptoms at rest), new-onset angina within  months before randomization, or myocardial infarction within  months before randomization.
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Unstable angina (angina symptoms at rest), new-onset angina (begun within the last  months) or myocardial infarction less than  months prior to randomization
History of clinically significant cardiac disease or congestive heart failure > New York Heart Association (NYHA) class ; patients must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last  months or myocardial infarction within the past  months
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
History of clinically significant cardiac disease or congestive heart failure > New York Heart Association (NYHA) class . Subjects must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last  months or myocardial infarction within the past  months.
Unstable angina (angina symptoms at rest), new-onset angina (begun within the last  months). Myocardial infarction less than  months before start of study treatment
Active or clinically significant cardiac disease including:\r\n* Congestive heart failure  New York Heart Association (NYHA) > class II\r\n* Uncontrolled cardiac arrhythmias despite optimal management\r\n* Unstable angina (anginal symptoms at rest), new-onset angina, myocardial infarction within  months of initiation of treatment on trial
Have congestive heart failure classified as New York Heart Association Class  or higher.Have had unstable angina (angina symptoms at rest) or new-onset angina ?  months prior to screening. Have had a myocardial infarction <  months prior to initiation of study treatment.
Serious illness including, significant ongoing or active infection, New York Heart Association (NYHA) grade III or IV congestive heart failure, unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy, thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within past  months; serious medical or psychiatric illness/social situations that in the opinion of the investigator would limit compliance with study requirements
Congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Cardiac disease: congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (angina symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Subject with uncontrolled cardiac disease including congestive heart failure class III or IV by the NYHA, unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Patients must not have cardiac disease defined as: New York Heart Association (NYHA) > class II; patients must not have unstable angina (angina symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Cardiac disease:\r\n* Congestive heart failure > class II New York Heart Association (NYHA), or\r\n* Unstable angina (anginal symptoms at rest), or new-onset angina (begun within the last  months), or myocardial infarction within the  months prior to enrollment, or \r\n* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\r\n* Congenital long QT syndrome or taking drugs known to prolong the QT interval\r\n* Subjects taking any drugs with a known risk of causing torsades de pointes
Congestive heart failure > class II New York Heart Association (NYHA); unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA): unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months, or uncontrolled arrhythmia
Congestive heart failure > class II New York Heart Association (NYHA); patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last  months) or myocardial infarction within the past  months
